Fig. 6

Fexofenadine alleviates the spread of α-syn pathology in C. elegans. a, b Alteration of VENUS-BiFC fluorescence in Tg models with fexofenadine at day 13. The red arrowheads point to VENUS-positive inclusions in the pharynx. Twenty-five worms for each line were used (n = 3 in each group). Scale bar indicates 20 μm. *p < 0.05, unpaired t-test. c–e VENUS-BiFC positive inclusions at day 13. c Worms with VENUS-BiFC positive inclusions were quantified at day 13. The number of inclusions in each group (d) and in three independent lines (e) are displayed as scatter plots. Twenty-five worms for each line were used (n = 3 in each group). *p < 0.05, unpaired t-test. f–h Change in blebbing phenotype in URA motor neurons. f Worms with axonal blebs were quantified. Axonal bleb numbers in respective Tg group (g) and in different lines (h) were plotted. Twenty-five worms for each line were used (n = 3 in each group). *p < 0.05, unpaired t-test. i Pharyngeal pumping rates with treatment of fexofenadine at day 8. Thirty worms for different line were used (n = 3 in each group). *p < 0.05, one-way ANOVA with Tukey’s multiple comparison test. j Mean lifespan analysis. One hundred worms for each line were examined (n = 3 in each group). *p < 0.05, one-way ANOVA with Tukey’s multiple comparison test